Skip to main content

Research Repository

Advanced Search

Disease-modifying trials in Alzheimer's disease: a European task force consensus

Vellas, Bruno; Sampaio, Cristina; Andrieu, Sandrine; Wilcock, Gordon

Authors

Bruno Vellas

Cristina Sampaio

Sandrine Andrieu

Gordon Wilcock



Abstract

After symptomatic treatments, the new target for therapeutic approaches in Alzheimer's disease is the development of disease-modifying drugs. The concept of disease modification in Alzheimer's disease is controversial and the design of these trials raises many questions. Which populations should be studied? For how long? With which principal and secondary endpoints? Are surrogate markers available? Here, we present a European consensus on disease-modifying trials in Alzheimer's disease, agreed under the auspices of the European Alzheimer's Disease Consortium and based on the European perspective of the concept of disease modification, study designs, the role for biomarkers, risk benefit, and pharmacoeconomic issues. © 2006 Elsevier Ltd. All rights reserved.

Citation

Vellas, B., Sampaio, C., Andrieu, S., & Wilcock, G. (2007). Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurology, 6(1), 56-62. https://doi.org/10.1016/S1474-4422%2806%2970677-9

Journal Article Type Review
Publication Date Jan 1, 2007
Journal Lancet Neurology
Print ISSN 1474-4422
Publisher Elsevier
Peer Reviewed Not Peer Reviewed
Volume 6
Issue 1
Pages 56-62
DOI https://doi.org/10.1016/S1474-4422%2806%2970677-9
Keywords disease-modifying trials, Alzheimer's disease, European task force
Public URL https://uwe-repository.worktribe.com/output/1031522
Publisher URL http://dx.doi.org/10.1016/S1474-4422(06)70677-9


Downloadable Citations